Nadia Galluccio

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Chiara Cremolini et al. · British Journal of Cancer · 2009 · 561 citations · Full text

Medicine, Genetics, Oncology +17

Genetic Activation of the <i>MET</i> Pathway and Prognosis of Patients With High-Risk, Radically Resected Gastric Cancer

Francesco Graziano, Nadia Galluccio, Paola Lorenzini et al. · Journal of Clinical Oncology · 2011 · 164 citations

Medicine, Genetics, Oncology +17

Genetic modulation of the Let-7 microRNA binding to KRAS 3′-untranslated region and survival of metastatic colorectal cancer patients treated with salvage cetuximab–irinotecan

Francesco Graziano, Emanuele Canestrari, Fotios Loupakis et al. · The Pharmacogenomics Journal · 2010 · 115 citations

Life Sciences, Molecular Biology, Oncology +17

High Let-7a MicroRNA Levels in <i>KRAS</i>-Mutated Colorectal Carcinomas May Rescue Anti-EGFR Therapy Effects in Patients with Chemotherapy-Refractory Metastatic Disease

Annamaria Ruzzo, Francesco Graziano, Bruno Vincenzi et al. · The Oncologist · 2012 · 76 citations · Full text

Medicine, Oncology, Pharmacology +17

Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancer

Fotios Loupakis, Annamaria Ruzzo, Lisa Salvatore et al. · BMC Cancer · 2011 · 74 citations · Full text

Medicine, Genetics, Oncology +15